vs
纽约时报公司（NYT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
纽约时报公司的季度营收约是Revvity的1.0倍（$802.3M vs $772.1M），纽约时报公司净利率更高（16.2% vs 12.7%，领先3.4%），纽约时报公司同比增速更快（10.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $157.6M），过去两年纽约时报公司的营收复合增速更高（16.2% vs 9.0%）
纽约时报公司是美国知名大众传媒企业，总部位于纽约市曼哈顿的纽约时报大厦，旗下核心出版产品包括《纽约时报》及其国际版等系列刊物，同时运营多元媒体资产，在全球新闻传媒领域拥有较高知名度。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NYT vs RVTY — 直观对比
营收规模更大
NYT
是对方的1.0倍
$772.1M
营收增速更快
NYT
高出4.6%
5.9%
净利率更高
NYT
高出3.4%
12.7%
自由现金流更多
RVTY
多$4.2M
$157.6M
两年增速更快
NYT
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $802.3M | $772.1M |
| 净利润 | $129.8M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 20.1% | 14.5% |
| 净利率 | 16.2% | 12.7% |
| 营收同比 | 10.4% | 5.9% |
| 净利润同比 | 4.9% | 3.9% |
| 每股收益（稀释后） | $0.79 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NYTRVTY
| Q4 25 | $802.3M | $772.1M | ||
| Q3 25 | $700.8M | $698.9M | ||
| Q2 25 | $685.9M | $720.3M | ||
| Q1 25 | $635.9M | $664.8M | ||
| Q4 24 | $726.6M | $729.4M | ||
| Q3 24 | $640.2M | $684.0M | ||
| Q2 24 | $625.1M | $691.7M | ||
| Q1 24 | $594.0M | $649.9M |
净利润NYTRVTY
| Q4 25 | $129.8M | $98.4M | ||
| Q3 25 | $81.6M | $46.7M | ||
| Q2 25 | $82.9M | $53.9M | ||
| Q1 25 | $49.6M | $42.2M | ||
| Q4 24 | $123.7M | $94.6M | ||
| Q3 24 | $64.1M | $94.4M | ||
| Q2 24 | $65.5M | $55.4M | ||
| Q1 24 | $40.4M | $26.0M |
毛利率NYTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率NYTRVTY
| Q4 25 | 20.1% | 14.5% | ||
| Q3 25 | 15.0% | 11.7% | ||
| Q2 25 | 15.5% | 12.6% | ||
| Q1 25 | 9.2% | 10.9% | ||
| Q4 24 | 20.2% | 16.3% | ||
| Q3 24 | 12.0% | 14.3% | ||
| Q2 24 | 12.7% | 12.4% | ||
| Q1 24 | 8.1% | 6.8% |
净利率NYTRVTY
| Q4 25 | 16.2% | 12.7% | ||
| Q3 25 | 11.7% | 6.7% | ||
| Q2 25 | 12.1% | 7.5% | ||
| Q1 25 | 7.8% | 6.4% | ||
| Q4 24 | 17.0% | 13.0% | ||
| Q3 24 | 10.0% | 13.8% | ||
| Q2 24 | 10.5% | 8.0% | ||
| Q1 24 | 6.8% | 4.0% |
每股收益（稀释后）NYTRVTY
| Q4 25 | $0.79 | $0.86 | ||
| Q3 25 | $0.50 | $0.40 | ||
| Q2 25 | $0.50 | $0.46 | ||
| Q1 25 | $0.30 | $0.35 | ||
| Q4 24 | $0.74 | $0.77 | ||
| Q3 24 | $0.39 | $0.77 | ||
| Q2 24 | $0.40 | $0.45 | ||
| Q1 24 | $0.24 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $642.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $7.3B |
| 总资产 | $3.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NYTRVTY
| Q4 25 | $642.2M | $919.9M | ||
| Q3 25 | $617.4M | $931.4M | ||
| Q2 25 | $540.2M | $991.8M | ||
| Q1 25 | $522.1M | $1.1B | ||
| Q4 24 | $565.9M | $1.2B | ||
| Q3 24 | $492.9M | $1.2B | ||
| Q2 24 | $411.4M | $2.0B | ||
| Q1 24 | $379.1M | $1.7B |
股东权益NYTRVTY
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $2.0B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.9B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.7B | $7.8B |
总资产NYTRVTY
| Q4 25 | $3.0B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.8B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.6B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $157.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 19.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.26× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $550.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流NYTRVTY
| Q4 25 | $164.2M | $182.0M | ||
| Q3 25 | $207.6M | $138.5M | ||
| Q2 25 | $113.6M | $134.3M | ||
| Q1 25 | $99.1M | $128.2M | ||
| Q4 24 | $151.7M | $174.2M | ||
| Q3 24 | $125.5M | $147.9M | ||
| Q2 24 | $80.2M | $158.6M | ||
| Q1 24 | $53.1M | $147.6M |
自由现金流NYTRVTY
| Q4 25 | $157.6M | $161.8M | ||
| Q3 25 | $199.7M | $120.0M | ||
| Q2 25 | $103.3M | $115.5M | ||
| Q1 25 | $89.9M | $112.2M | ||
| Q4 24 | $143.6M | $149.8M | ||
| Q3 24 | $118.4M | $125.6M | ||
| Q2 24 | $72.6M | $136.6M | ||
| Q1 24 | $46.7M | $129.7M |
自由现金流率NYTRVTY
| Q4 25 | 19.6% | 21.0% | ||
| Q3 25 | 28.5% | 17.2% | ||
| Q2 25 | 15.1% | 16.0% | ||
| Q1 25 | 14.1% | 16.9% | ||
| Q4 24 | 19.8% | 20.5% | ||
| Q3 24 | 18.5% | 18.4% | ||
| Q2 24 | 11.6% | 19.7% | ||
| Q1 24 | 7.9% | 20.0% |
资本支出强度NYTRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 1.1% | 3.4% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 1.2% | 3.2% | ||
| Q1 24 | 1.1% | 2.7% |
现金转化率NYTRVTY
| Q4 25 | 1.26× | 1.85× | ||
| Q3 25 | 2.54× | 2.97× | ||
| Q2 25 | 1.37× | 2.49× | ||
| Q1 25 | 2.00× | 3.03× | ||
| Q4 24 | 1.23× | 1.84× | ||
| Q3 24 | 1.96× | 1.57× | ||
| Q2 24 | 1.22× | 2.87× | ||
| Q1 24 | 1.31× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NYT
| Subscription | $510.5M | 64% |
| Advertising | $191.7M | 24% |
| Affiliate Licensing And Other Products And Services | $100.2M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
